From Early-Stage Innovations to Global Market Maturity

Sanara Ventures partners with and invests in healthcare startups, towards global market growth…
read more about our value proposition

Where We Seek to Invest

We seek outstanding healthcare technologies, created by inspiring people, in a wide areas of market categories.
More here about our investment focus areas

Our Portfolio of Unique Innovative Companies

We are proud to invest and assist a unique team of innovators and promising companies.
Our initial investments, will be presented soon.

Sanara Ventures is a Joint Venture of

Wordmark_2008_RGB_small         logo-teva

About Us

Sanara Ventures is an innovation-investment platform, elevating outstanding healthcare-technology companies, from early-stage to global market maturity. At Sanara, we share a vision of an integrated continuum of care supported by accessible advanced healthcare solutions for people around the world.

Sanara aims to generate real positive impact on medical conditions and medical-systems by providing funding and mentoring to early stage medical technology companies. Sanara provides its portfolio companies with an unmatched network of global experts and specialists in a wide range of technology and clinical fields to allow acceleration and optimization of development and commercialization processes. Additionally, fast access to markets for validating new venture ideas is available through vast client footprint.

Sanara was established by Teva Pharmaceuticals and Philips healthcare, two of the world’s leading pharmaceutical and healthcare technology players, in collaboration with the Office of the Chief Scientist of the Israeli Ministry of the Economy, as an independent joint-venture.

Our Shareholders


Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion.
Teva aims to build a powerful scientific environment that will improve quality of life of millions of people around the globe. Sanara Ventures, the unique collaboration by Teva and Philips, expresses this commitment and Teva’s faith in the contribution the state of Israel can have to its future development.


Royal Philips is a diversified health-tech and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 105,000 employees with sales and services in more than 100 countries.
The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. The company’s vision is to make the world healthier and more sustainable through innovation.


Our name, Sanara resonates the Latin word Sanàre,
which means to heal and cure, but also to improve, put-right and settle.
Sanara for us, is a visionary and meaningful point of view
on the future of health and wellbeing of people around the world

Where We Add Value

Backed by our experience, market footprint and financial backbone, we support entrepreneurial companies from their first steps to their full commercialization and market-maturity.

Early Acceleration

Mentorship and small-scale funding to achieve initial technology validation within 2-3 months.

Seed-Need Package

Incubator based financial, technology & business support with sufficient supplementary funding to achieve Proof of Concept within 15-24 months.

R&D Mentoring

Technical support from Philips & Teva experts and global Key Opinion Leaders to achieve acceleration and optimization processes.

Market validation

Quick access to markets through vast network of Philips’ and Teva’s clients, consultants and opinion leaders and exposure to world medical leaders.

International Business Development

Acceleration of go-to-market processes and industry connections aiming to create mature companies ready for their next stage.

A/B/C Funding

Post incubation investments or investments in other, non-incubator, mature companies.

Our Focus

We look for outstanding technologies driven by exceptional people.
We seek to invest in medical devices and healthcare technologies that innovate in these industry categories:

Digital Health, Healthcare IT and Mobile Apps

Digital technologies that allow ‘beyond the pill’ solutions, maximize efficiency, quality & tracking of healthcare delivery & make medicine more personalized and precise.

Continuum of Care and Disease Management

Improved care coordination, bringing a team-based approach & shifting focus from episodes of hospitalization to prevention, early diagnosis and disease management.

Patient Diagnosis, Sensing and Monitoring

Advanced sensor technologies and patient monitoring solutions, supporting decision-making and helping improve patient care at the hospital and at home.

Emerging Imaging Modalities

Functional, molecular and structural imaging modalities assisted by augmented reality solutions, for better anatomical visualization at lower radiation.

Drug Delivery and Drug Device Combinations

Approaches and technologies for transportation of medicines in the body, to achieve better therapeutic effect. Specifically in respiratory, degenerative diseases & pain management.

Minimally Invasive Device Technologies

Minimally invasive interventional devices that simplify procedures and improve outcomes at a lower cost.


A hand-held nebulizer allowing quicker and more efficient pulmonary drug administration
Read more
Meway Pharma
Drug delivery
A handheld device for comprehensive lung function testing in the clinic or at home
Read more
Home monitoring & management
An innovative affordable home solution for remote checkups and diagnosis based on a smartphone
Read more
my HomeDoc
Digital health
Disease management solution for Asthma, based on a low cost spirometer and an App
Read more
Home monitoring & management
LensFree Imaging's technology will reduce radiation exposure in CT scanners by 50%
Read more
LensFree Imaging
PURECARE home device delivers medical-quality ozonated water to disinfect gums and thus prevent and treat gum diseases
Read more
Oral Hygene
Platform technology for single cell analysis of cancer tumor cells
Read more
OneCell Medical
Cancer Diagnostics
TailorMed's addresses the financial toxicity of chronic and life-threatening diseases.

Read more
Digital Health
Lifegraph detects changes in smartphone use patterns to predict migraine attacks.
Read more
Digital Health
Lydus develops innovative tools for anastomosis of small vessels.
Read more
Lydus Medical
Surgical tools
AI technology for quality assurance and risk management in radiology
Read more
Digital Health

The Team

Assaf Barnea
Chief Executive Officer
Aimee Fisher
VP Business Development
Eran Toledo
Chief Technology Officer
Doron Gerassi
Chief Financial Officer
Pinchas (Pinny) Halpern
Chief Medical Officer
Hila Zur
Administrative manager and PA

Board Members

Bert van Meurs
Senior Vice President, CEO Image Guided Therapy, Royal Philips, Chairman Philips Medical Systems Nederland BV
Jan Kimpen
Chief Medical Officer, Philips Healthcare
Yair Briman
General Manager of Healthcare IT, Philips HealthTech
Avinoam Sapir
CEO, Teva Israel
Yossi Ofek
Managing Director at Pharma Innovative Solutions, Teva Israel
Mati Gill
Head of Government Affairs, Corporate HQ and Growth Markets, Teva Pharmaceuticals

News @ Sanara Ventures

From Basketball to healthcare innovation

The story of Assaf Barnea and how he ended up in Sanara. Read the full article…


Medical tests moving to home

Medical tests are sometimes best done at home – a recent lesson from a startup competition…


Teva-Philips Israel incubator selects 9 projects

  Sanara Ventures CEO Assaf Barnea: Over the past year we checked out 750 potential projects…


Sanara Ventures cements Teva-Philips ties

Assaf Barnea, who leads the Teva-Philips funded Sanara Ventures, opens up about the incubator’s initial investments. “In…


Sanara’s CEO Assaf Barnea participates in a video panel of Calcalist Newspaper (Hebrew),7340,L-3677189,00.html          


Sanara Ventures participates in the first Digital Health Meetup in Haifa

Public Health in a digital world On Nov 23, 2015 Sanara Ventures participated in the first…


Teva and Philips Join Forces to Tackle Medtech / The MedTech Strategist

Sanara Ventures: Teva and Philips Join Forces to Tackle Medtech By David Cassak Key Points: -…


Philips CEO: Israel has major role in our vision

Frans van Houten tells “Globes” that Philip’s focus on technology for medicine means Israel will become…


Sanara Ventures Announces First Two Investments

Sanara Ventures Ltd. (Sanara), a new investment platform for early stage medical device and health technology…


Sanara Venture’s CEO Assaf Barnea at Teva Talk 2015 (ILSI Biomed)    


Teva, Philips Healthcare incubator begins operations

Sanara Ventures in Ra’anana will invest in medical devices and fields that complement drug development.  The…


Philips-Teva and Strauss win tech incubator tenders

The Philips-Teva incubator will focus on pharmaceuticals and medical devices, and the Strauss incubator on food-related…


Contact Us

Contact Us


13 Zarhin st
Building C
4366241 Ra’anana

Contact Details

Phone: +972 (76) 8899800